Alex­ion pays $930M to buy out Achillion and its promis­ing com­pan­ion drug to Soliris

Af­ter a se­ries of stock-crunch­ing set­backs over the years, Achillion en­joyed a turn in the sun a few weeks ago as the FDA blessed their lead drug dan­i­co­pan (ACH-4471) — a com­ple­men­tary ther­a­py for PNH pa­tients tak­ing Alex­ion’s Soliris — with a break­through drug des­ig­na­tion af­ter tak­ing a look at some sol­id sup­port­ing Phase II da­ta.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER